Efficacy and safety of dupilumab for moderate‐to‐severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines

  • Ioana Agache
    Faculty of Medicine Transylvania University Brasov Romania
  • Yang Song
    Department of Clinical Epidemiology and Public Health Iberoamerican Cochrane Centre Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
  • Margarita Posso
    Department of Clinical Epidemiology and Public Health Iberoamerican Cochrane Centre Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
  • Pablo Alonso‐Coello
    Department of Clinical Epidemiology and Public Health Iberoamerican Cochrane Centre Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
  • Claudio Rocha
    Department of Clinical Epidemiology and Public Health Iberoamerican Cochrane Centre Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
  • Ivan Solà
    Department of Clinical Epidemiology and Public Health Iberoamerican Cochrane Centre Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
  • Jessica Beltran
    Department of Clinical Epidemiology and Public Health Iberoamerican Cochrane Centre Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
  • Cezmi A. Akdis
    Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Davos Switzerland
  • Mubeccel Akdis
    Swiss Institute of Allergy and Asthma Research (SIAF) University of Zurich Davos Switzerland
  • Knut Brockow
    Department of Dermatology and Allergology Biederstein Technical University of Munich Munich Germany
  • Tomas Chivato
    School of Medicine University CEU San Pablo Madrid Spain
  • Stefano del Giacco
    Department of Medical Sciences and Public Health University of Cagliari Cagliari Italy
  • Thomas Eiwegger
    Translational Medicine Program, Research Institute Hospital for Sick Children Toronto ON Canada
  • Kilian Eyerich
    Department of Dermatology and Allergy Biederstein Technical University of Munich Munich Germany
  • Ana Giménez‐Arnau
    Department of Dermatology Hospital del Mar‐ Institut Mar d'Investigacions Mèdiques Universitat Autònoma de Barcelona Bellaterra Spain
  • Jan Gutermuth
    Department of Dermatology Universitair Ziekenhuis Brussel Vrije Universiteit Brussel (VUB) Brussels Belgium
  • Emma Guttman‐Yassky
    Department of Dermatology Icahn School of Medicine at Mount Sinai New York NY USA
  • Marcus Maurer
    Dermatological Allergology Allergie‐Centrum‐Charité Department of Dermatology and Allergy Charité ‐ Universitätsmedizin Berlin Berlin Germany
  • Graham Ogg
    MRC Human Immunology Unit MRC Weatherall Institute of Molecular Medicine Oxford NIHR Biomedical Research Centre Radcliffe Department of Medicine University of Oxford Oxford UK
  • Peck Y. Ong
    Division of Clinical Immunology & Allergy Children’s Hospital Los Angeles Keck School of Medicine University of Southern California Los Angeles CA USA
  • Liam O’Mahony
    Departments of Medicine and Microbiology APC Microbiome Ireland University College Cork Cork Ireland
  • Jürgen Schwarze
    Centre for Inflammation Research Child Life and Health The University of Edinburgh Edinburgh UK
  • Thomas Werfel
    Division of Immunodermatology and Allergy Research Department of Dermatology and Allergy Hannover Medical School Hannover Germany
  • Carlos Canelo‐Aybar
    Department of Clinical Epidemiology and Public Health Iberoamerican Cochrane Centre Biomedical Research Institute Sant Pau (IIB Sant Pau) Barcelona Spain
  • Oscar Palomares
    Department of Biochemistry and Molecular Biology Chemistry School Complutense University of Madrid Madrid Spain
  • Marek Jutel
    Department of Clinical Immunology Wroclaw Medical University Wroclaw Poland

抄録

<jats:title>Abstract</jats:title><jats:p>This systematic review evaluates the efficacy, safety and economic impact of dupilumab compared to standard of care for uncontrolled moderate‐to‐severe atopic dermatitis (AD). Pubmed, EMBASE and Cochrane Library were searched for RCTs and health economic evaluations. Critical and important AD‐related outcomes were considered. The risk of bias and the certainty of the evidence were assessed using GRADE. Seven RCTs including 1845 subjects >12 years treated with dupilumab 16 to 52 weeks were evaluated. For adults, there is high certainty that dupilumab decreases SCORAD (MD −30,72; 95% CI −34,65% to −26,79%) and EASI‐75 (RR 3.09; 95% CI 2.45 to 3.89), pruritus (RR 2.96; 95% CI 2.37 to 3.70), rescue medication (RR 3.46; 95% CI 2.79 to 4.30), sleep disturbance (MD −7.29; 95% CI −8.23 to −6.35) and anxiety/depression (MD −3.08; 95% CI −4.41 to −1.75) and improves quality of life (MD −4.80; 95% CI −5.55 to −4.06). The efficacy for adolescents is similar. Dupilumab‐related adverse events (AEs) slightly increase (low certainty). The evidence for dupilumab‐related serious AE is uncertain. The incremental cost‐effectiveness ratio ranged from 28 500 £ (low certainty) to 124 541 US$ (moderate certainty). More data on long‐term safety are needed both for children and for adults, together with more efficacy data in the paediatric population. <jats:bold>Registration</jats:bold>: PROSPERO (CRD42020153645).</jats:p>

収録刊行物

  • Allergy

    Allergy 76 (1), 45-58, 2020-10-04

    Wiley

被引用文献 (1)*注記

もっと見る

問題の指摘

ページトップへ